CA-PULMONX
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) this week issued a substantial revision to its management recommendations for chronic obstructive pulmonary disease (COPD) that, for the first time, includes bronchoscopic lung volume reduction using endobronchial valves as a treatment option for patients with advanced emphysema and absence of collateral ventilation. The updated recommendations are based on new clinical evidence published in the past 15 months supporting the Zephyr® Endobronchial Valve (EBV), including three randomized controlled trials (BeLieVeR-HIFi , STELVIO and IMPACT ).
In describing the clinical evidence to support this recommendation, the GOLD report notes, “In select patients with advanced emphysema, bronchoscopic interventions reduce end-expiratory lung volume and improves exercise tolerance, health status and lung function 6-12 months following treatment.“
“This is the first major update to the GOLD guidance for bronchoscopic interventions, based on recent data,” said Professor Felix Herth, Head of the Department of Internal Medicine, Pulmonology and Critical Care Medicine, Thoraxklinik Heidelberg, Germany. “These interventions offer promise for emphysema patients who continue to suffer symptoms, despite optimal pharmacologic management.”
Zephyr EBVs are tiny, minimally-invasive, one-way valves placed in select airways of the lungs to occlude diseased regions and reduce lung hyperinflation. As a result, the remaining healthier regions may function more efficiently, enabling better breathing and an improved quality of life for patients.
Each year, GOLD issues a report entitled “Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease,” which is used worldwide as a “strategy” document for healthcare professionals to implement effective management programs based on local healthcare systems. The report issues recommendations for the management of COPD based on the best scientific information available.
“With our tools to help physicians identify the best responders to endobronchial valve treatment, Pulmonx is enabling precision medicine for the treatment of emphysema,” said Glen French, Pulmonx chief executive officer. “We welcome this recognition of the growing body of evidence demonstrating the benefit of EBV treatment for emphysema patients.”
Over the past 10 years, more than 48,000 Zephyr EBVs have been implanted globally in more than 12,000 patients. To view a video of the Zephyr EBV procedure, click here .
About Pulmonx
Based in Redwood City, California, and Neuchâtel, Switzerland, Pulmonx is an interventional pulmonology company focused on developing life-changing, cost-effective technologies that improve the lives of patients suffering from lung disease worldwide. For more information, visit www.pulmonx.com .
The Zephyr EBV is an investigational device in the United States. Limited by U.S. law to investigational use only.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161118005704/en/
Contact:
Chronic Communications
Michelle McAdam, (949) 545-6654 or (310)
902-1274
michelle@chronic-comm.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doha Debates Asks: Is ‘Earned Success’ an Illusion?13.11.2025 14:55:00 CET | Press release
Global thinkers and students in Doha engage in a spirited debate over fairness, privilege and the meaning of success. Can success ever be truly earned? In its latest flagship episode, Qatar Foundation’s Doha Debates brings together global thinkers and students for a thought-provoking conversation on whether hard work and talent still determine who rises, or whether “earned success” conceals deeper inequities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251113305464/en/ Doha Debates brings together global thinkers and students for a thought-provoking conversation on whether hard work and talent still determine who rises, or whether “earned success” conceals deeper inequities. (Photo: AETOSWire) Daniel Markovits, Guido Calabresi Professor of Law at Yale Law School, argues that the system meant to promote fairness has instead entrenched inequality. “Meritocracy has become the principal obstacle to equality of opportunity, at
FlightSafety International Announces Release of Industry-Wide Airplane Standard Operating Procedures to Elevate Safety in Business Aviation13.11.2025 14:45:00 CET | Press release
The manual represents the culmination of years of shared commitment by FlightSafety and industry partners to elevate safety. FlightSafety International Inc. today announced the publication of the Airplane Standard Operating Procedures Manual, a landmark resource that establishes consistent, proven practices for business aviation operations worldwide. Developed in collaboration with the National Business Aviation Association (NBAA), aircraft manufacturers, operators, and other leading training experts, the SOPs represent years of industry partnership dedicated to advancing aviation safety. The new manual provides uniform guidance for both single- and multi-pilot operations, reflecting best practices drawn from organizations of all sizes. By promoting widespread adoption of standardized procedures, the SOPs will strengthen consistency across fleets, enhance safety in dynamic crew environments, and generate valuable data to inform future training improvements. “FlightSafety International
Experian Named One of the World’s Best Workplaces™ for Second Consecutive Year13.11.2025 14:12:00 CET | Press release
Experian has once again been recognised by Fortune and Great Place to Work® as one of the World’s Best Workplaces™ 2025, marking its second consecutive year on this prestigious global list. This honor places Experian among the top 25 companies worldwide celebrated for exceptional workplace culture, inclusivity, and employee experience. These 25 global leaders were selected from organizations that participated in Great Place to Work’s employee survey process, with over 9 million responses representing more than 25 million employees worldwide. To be considered for the list, companies must have 5,000 or more global employees, be identified as outstanding global employers with recognition on at least five Best Workplaces™ Lists in Asia, Europe, Latin America, Africa, North America, or Australia in 2024 or early 2025. “This award recognizes our people-first culture and our commitment to creating an environment where everyone can thrive,” said Brian Cassin, Experian Chief Executive Officer.
Mary Kay Ash Foundation® Gifts $500,000 Grant to Advance Cancer Research and Early Detection at Baylor Scott & White Health13.11.2025 14:01:00 CET | Press release
Funding includes support for groundbreaking clinical trial and multi-year gift to Texas Cancer Interception Institute; Foundation honored with Circle of Care Award for two decades of partnership The Mary Kay Ash Foundation®, a champion of women’s health innovation for nearly three decades, announced a $500,000 grant to Baylor Scott & White Dallas Foundation to accelerate a pioneering triple-negative breast cancer clinical trial and advance early detection initiatives that shift care from reactive to proactive at the newly established Texas Cancer Interception Institute. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251113339900/en/ In recognition of its steadfast, decades-long commitment to women’s health, the Mary Kay Ash Foundation was honored with the prestigious Circle of Care Award at the 2025 Celebrating Women Luncheon, hosted by the Baylor Scott & White Dallas Foundation. The award celebrates those who have made a pr
Owkin Announces Availability of K Pro in the AWS Marketplace SaaS Category13.11.2025 14:00:00 CET | Press release
Owkin, a leading provider of agentic AI solutions for biopharma, today announced the availability of K Pro in the SaaS category of AWS Marketplace. Customers can now use AWS Marketplace to easily discover, buy, and deploy AI agents solutions, including Owkin’s agentic AI co-pilot for biopharma using their AWS accounts, accelerating agent and agentic workflow development. K Pro helps organizations make smarter decisions across their discovery and development pipeline by delivering decision-grade, data-driven biological insights, enabling customers to increase clinical success rates and change program trajectories. "By offering K Pro in AWS Marketplace we're providing customers with a streamlined way to access our agentic AI co-pilot, helping them buy and deploy agent solutions faster and more efficiently." said Adi Ravia, Head of Product at Owkin. "Our customers in biotech, pharmaceuticals and research are already using these capabilities to access and analyse deep multimodal patient da
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom